Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials

Overview

Journal Annu Rev Pathol

Publisher Annual Reviews

Specialty Pathology

Date 2016 Dec 14

PMID 27959633

Citations 28

Authors

Jonathan H Esensten

Jeffrey A Bluestone

Wendell A Lim

Affiliations

Soon will be listed here.

Abstract

Engineered T cells are currently in clinical trials to treat patients with cancer, solid organ transplants, and autoimmune diseases. However, the field is still in its infancy. The design, and manufacturing, of T cell therapies is not standardized and is performed mostly in academic settings by competing groups. Reliable methods to define dose and pharmacokinetics of T cell therapies need to be developed. As of mid-2016, there are no US Food and Drug Administration (FDA)-approved T cell therapeutics on the market, and FDA regulations are only slowly adapting to the new technologies. Further development of engineered T cell therapies requires advances in immunology, synthetic biology, manufacturing processes, and government regulation. In this review, we outline some of these challenges and discuss the contributions that pathologists can make to this emerging field.

Citing Articles

Interfacing Living and Synthetic Cells as an Emerging Frontier in Synthetic Biology.

Elani Y Angew Chem Weinheim Bergstr Ger. 2024; 133(11):5662-5671.

PMID: 38505493 PMC: 10946473. DOI: 10.1002/ange.202006941.

The present and future of bispecific antibodies for cancer therapy.

Klein C, Brinkmann U, Reichert J, Kontermann R Nat Rev Drug Discov. 2024; 23(4):301-319.

PMID: 38448606 DOI: 10.1038/s41573-024-00896-6.

Conditional Control of Universal CAR T Cells by Cleavable OFF-Switch Adaptors.

Kvorjak M, Ruffo E, Tivon Y, So V, Parikh A, Deiters A ACS Synth Biol. 2023; 12(10):2996-3007.

PMID: 37791909 PMC: 10594876. DOI: 10.1021/acssynbio.3c00320.

Modular pooled discovery of synthetic knockin sequences to program durable cell therapies.

Blaeschke F, Chen Y, Apathy R, Daniel B, Chen A, Chen P Cell. 2023; 186(19):4216-4234.e33.

PMID: 37714135 PMC: 10508323. DOI: 10.1016/j.cell.2023.08.013.

Conditional control of universal CAR T cells by cleavable OFF-switch adaptors.

Kvorjak M, Ruffo E, Tivon Y, So V, Parikh A, Deiters A bioRxiv. 2023; .

PMID: 37292935 PMC: 10245878. DOI: 10.1101/2023.05.22.541664.

References

Garfall A, Maus M, Hwang W, Lacey S, Mahnke Y, Melenhorst J . Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med. 2015; 373(11):1040-7. PMC: 4646711. DOI: 10.1056/NEJMoa1504542. View

Bailey A, Arcidiacono J, Benton K, Taraporewala Z, Winitsky S . United States Food and Drug Administration Regulation of Gene and Cell Therapies. Adv Exp Med Biol. 2015; 871:1-29. DOI: 10.1007/978-3-319-18618-4_1. View

Kolb H, Schmid C, Barrett A, Schendel D . Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2003; 103(3):767-76. DOI: 10.1182/blood-2003-02-0342. View

Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S . Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009; 326(5959):1509-12. DOI: 10.1126/science.1178811. View

Turchiano G, Latella M, Gogol-Doring A, Cattoglio C, Mavilio F, Izsvak Z . Genomic analysis of Sleeping Beauty transposon integration in human somatic cells. PLoS One. 2014; 9(11):e112712. PMC: 4229213. DOI: 10.1371/journal.pone.0112712. View

Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z . Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012; 18(23):6436-45. DOI: 10.1158/1078-0432.CCR-12-1449. View

Leen A, Bollard C, Mendizabal A, Shpall E, Szabolcs P, Antin J . Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013; 121(26):5113-23. PMC: 3695359. DOI: 10.1182/blood-2013-02-486324. View

Wang J, DeClercq J, Hayward S, Li P, Shivak D, Gregory P . Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res. 2015; 44(3):e30. PMC: 4756813. DOI: 10.1093/nar/gkv1121. View

Zhou X, Di Stasi A, Tey S, Krance R, Martinez C, Leung K . Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014; 123(25):3895-905. PMC: 4064331. DOI: 10.1182/blood-2014-01-551671. View

10.

Kim H, Kim J . A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014; 15(5):321-34. DOI: 10.1038/nrg3686. View

11.

Hacein-Bey-Abina S, Garrigue A, Wang G, Soulier J, Lim A, Morillon E . Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008; 118(9):3132-42. PMC: 2496963. DOI: 10.1172/JCI35700. View

12.

Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman M . Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009; 17(11):1919-28. PMC: 2835038. DOI: 10.1038/mt.2009.179. View

13.

Weissinger E, Borchers S, Silvani A, Provasi E, Radrizzani M, Beckmann I . Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells. Front Pharmacol. 2015; 6:76. PMC: 4407574. DOI: 10.3389/fphar.2015.00076. View

14.

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L . HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997; 276(5319):1719-24. DOI: 10.1126/science.276.5319.1719. View

15.

Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K . Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012; 4(132):132ra53. PMC: 4368443. DOI: 10.1126/scitranslmed.3003761. View

16.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

17.

Yannelli J, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L . Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer. 1996; 65(4):413-21. DOI: 10.1002/(SICI)1097-0215(19960208)65:4<413::AID-IJC3>3.0.CO;2-#. View

18.

Riteau B, Menier C, Martinozzi S, Pla M, Dausset J, Carosella E . HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol. 2001; 13(2):193-201. DOI: 10.1093/intimm/13.2.193. View

19.

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

20.

Budde L, Berger C, Lin Y, Wang J, Lin X, Frayo S . Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One. 2013; 8(12):e82742. PMC: 3866194. DOI: 10.1371/journal.pone.0082742. View